tbuckley/cabot-search huggingface dataset:
Letter to the editor: GALAD score: Superior surveillance strategy or not?
Authors: Anurag Sachan, Saraswati Kushwah
Journal: Hepatology (2022)

To the editor, We read with great interest the study by Singal et al. and commend the authors for this large prospective cohort study.[1] The authors concluded that single point as well as longitudinal GALAD (Gender, Age, L3 fraction of alpha‐fetoprotein [AFP‐L3], alpha‐fetoprotein [AFP], des‐gamma carboxy prothrombin [DCP]) score has high sensitivity for early HCC detection when compared with individual component biomarkers of GALAD score and HCC early detection screening (HES). HCC has a significant benefit in prognosis with a surveillance program due to effective treatment when caught early. The current guidelines suggest use of abdominal ultrasound (US) with or without AFP for HCC surveillance. US has been criticized for operator dependence and decrease in sensitivity with obesity, NAFLD, and small tumor, particularly <2 cm.[2] For the requirement of a screening modality with better sensitivity, reproducibility, and accessibility, a blood‐based biomarker was suggested. A recent Cochrane meta‐analysis has shown that US is superior to AFP for resectable HCC and the combination outperforms them individually, with sensitivity reaching up to 89% and specificity up to 87%.[3] In a resource‐poor setting, cost becomes a major factor; the addition of multiple biomarkers increases the cost of surveillance, and no cost‐benefit analysis for GALAD score is available yet. Further, the morbidity attached with high false positivity rate (FPR) of 25% with the GALAD score can be alarming compared with 15% with US and AFP combination.[3,4] When adjusted for FPR, GALAD score does not outperform AFP‐L3 or HES.[4] Recently, an US‐free approach has been deemed to be a way forward with the availability of newer biomarkers and their combinations. Addition of DCP alone to AFP raises the sensitivity of detecting HCC to around 75% with a specificity >90% in a cohort of patients with chronic hepatitis B.[5] This combination was not compared in this study with GALAD and would be useful because this will reduce the cost of surveillance. A screening test should balance availability, affordability, and accuracy for its appropriate usage, and GALAD score may not fulfill this role in current practice. PATIENT AND PUBLIC INVOLVEMENT Patients and/or the public were not involved in the design, conduct, reporting, or dissemination of plans for this research. CONFLICT OF INTEREST None declared. AUTHOR CONTRIBUTIONS Anurag Sachan: Manuscript preparation and concept. Saraswati Kushwah: Manuscript preparation and critical review.
Genetic Testing in Newborns Moves From Rare to Routine Application
Authors: De-Ann M. Pillers
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
THE RELATION OF RENIN-ANGIOTENSIN-ALDOSTERONE-SYSTEM ACTIVITY AND ENDOTHELIN-1 LEVELS TO CORONARY ATHEROSCLEROTIC BURDEN AND MICROVASCULAR DYSFUNCTION IN SYMPTOMATIC CHEST PAIN PATIENTS
Authors: Ruurt Jukema, Ruben Willem De Winter, Pepijn Van Diemen, Roel Driessen, Jan Danser, Ingrid Garrelds, Pieter Raijmakers, Peter van de Ven, Paul Knaapen, Ibrahim Danad, Guus de Waard
Journal: Journal of the American College of Cardiology (2022)
Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S
Authors: Tom J Harryvan, Marten Visser, Linda de Bruin, Léonie Plug, Lisa Griffioen, Arend Mulder, Peter A van Veelen, Gerbrand J van der Heden van Noort, Marlieke LM Jongsma, Miranda H Meeuwsen, Emmanuel JHJ Wiertz, Saskia J Santegoets, James CH Hardwick, Thorbald Van Hall, Jacques Neefjes, Sjoerd H Van der Burg, Lukas JAC Hawinkels, Els ME Verdegaal
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Cross-presentation of exogenous antigens in HLA-class I molecules by professional antigen presenting cells (APCs) is crucial for CD8+ T cell function. Recent murine studies show that several non-professional APCs, including cancer-associated fibroblasts (CAFs) also possess this capacity. Whether human CAFs are able to cross-present exogenous antigen, which molecular pathways are involved in this process and how this ultimately affects tumor-specific CD8+ T cell function is unknown. Methods In this study, we investigated the ability of human colorectal cancer (CRC)-derived CAFs to cross-present neoantigen-derived synthetic long peptides (SLPs), corresponding to tumor-derived mutant peptides, and how this affects tumor-specific T-cell function. Processing of the SLP was studied by targeting components of the cross-presentation machinery through CRISPR/Cas9 and siRNA-mediated genetic ablation to identify the key molecules involved in fibroblast-mediated cross-presentation. Multispectral flow cytometry and killing assays were performed to study the effect of fibroblast cross-presentation on T cell function. Results Here, we show that human CRC-derived CAFs display an enhanced capacity to cross-present neoantigen-derived SLPs when compared with normal colonic fibroblasts. Cross-presentation of antigens by fibroblasts involved the lysosomal protease cathepsin S. Cathepsin S expression by CAFs was detected in situ in human CRC tissue, was upregulated in ex vivo cultured CRC-derived CAFs and showed increased expression in normal fibroblasts after exposure to CRC-conditioned medium. Cognate interaction between CD8+ T cells and cross-presenting CAFs suppressed T cell function, reflected by decreased cytotoxicity, reduced activation (CD137) and increased exhaustion (TIM3, LAG3 and CD39) marker expression. Conclusion These data indicate that CAFs may directly suppress tumor-specific T cell function in an antigen-dependent fashion in human CRC.
Invasive mould infections in patients from floodwater-damaged areas after hurricane Harvey – a closer look at an immunocompromised cancer patient population
Authors: Sebastian Wurster, Timotheos Paraskevopoulos, Mitsuru Toda, Ying Jiang, Jeffrey J Tarrand, Samantha Williams, Tom M Chiller, Brendan R Jackson, Dimitrios P Kontoyiannis
Journal: Journal of Infection (2022)
QT INTERVAL PROLONGATION IS A NOVEL PREDICTOR OF 1-YEAR MORTALITY IN PATIENTS WITH COVID-19 INFECTION
Authors: Ariel Banai, Yishay Szekely, Ariel Borohovitz, Lior Lupu, Erez Levy, Aviram Hochstadt, Eihab Ghantous, Philippe Taieb, Shmuel Banai, Yan Topilsky, Ehud Chorin
Journal: Journal of the American College of Cardiology (2022)
TEMPORAL TRENDS AND OUTCOMES OF TRANSCATHETER VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN PATIENTS WITH SARCOIDOSIS
Authors: Rahul Gupta, Aaqib Malik, Dhrubajyoti Bandyopadhyay, Umair Tariq, Lekha Racharla, Makoto Nagahama, Akhil Kher, Pallavi Satuluri, Apurva Vijay Vyas, Alexandros Briasoulis, Nainesh C. Patel, Hasan Ahmad
Journal: Journal of the American College of Cardiology (2022)
Effects of SARS-CoV-2 on prenatal lung growth assessed by fetal MRI
Authors: Sophia Stoecklein, Vanessa Koliogiannis, Tobias Prester, Thomas Kolben, Magdalena Jegen, Christoph Hübener, Uwe Hasbargen, Andreas Flemmer, Olaf Dietrich, Regina Schinner, Julien Dinkel, Nicola Fink, Maximilian Muenchhoff, Susan Hintz, Maria Delius, Sven Mahner, Jens Ricke, Anne Hilgendorff
Journal: The Lancet Respiratory Medicine (2022)
Traumatic Brain Injury in Older Adults—A Public Health Perspective
Authors: Dana Waltzman, Juliet Haarbauer-Krupa, Lindsay S. Womack
Journal: JAMA Neurology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
POOR INCREASE OF LEFT ATRIAL PRESSURE DURING TACHYCARDIA IS INVOLVED WITH THE DEVELOPMENT OF TACHYCARDIA INDUCED CARDIOMYOPATHY IN PATIENTS WITH ATRIAL FIBRILLATION
Authors: Eiji Fukuhara, Takanao Mine, Ryo Kitagaki, Masaharu Ishihara
Journal: Journal of the American College of Cardiology (2022)
U-Shaped Associations Between Body Weight Changes and Major Cardiovascular Events in Type 2 Diabetes Mellitus: A Longitudinal Follow-up Study of a Nationwide Cohort of Over 1.5 Million
Authors: Chan Soon Park, You-Jung Choi, Tae-Min Rhee, Hyun Jung Lee, Hee-Sun Lee, Jun-Bean Park, Yong-Jin Kim, Kyung-Do Han, Hyung-Kwan Kim
Journal: Diabetes Care (2022)

OBJECTIVE Despite the benefits of weight loss on metabolic profiles in patients with type 2 diabetes mellitus (T2DM), its association with myocardial infarction (MI), ischemic stroke (IS), atrial fibrillation (AF), heart failure (HF), and all-cause death remains elusive. RESEARCH DESIGN AND METHODS Using the National Health Insurance Service Database, we screened subjects who underwent general health checkups twice in a 2-year interval between 2009 and 2012. After identifying 1,522,241 patients with T2DM without a previous history of MI, IS, AF, and HF, we followed them until December 2018. Patients were stratified according to the magnitude of weight changes between two general health checkups: ≤ −10%, −10 to ≤ −5%, −5 to ≤5%, 5 to ≤10%, and &amp;gt;10%. Results During the follow-up (median 7.0 years), 32,106 cases of MI, 44,406 cases of IS, 34,953 cases of AF, 68,745 cases of HF, and 84,635 all-cause deaths occurred. Patients with weight changes of −5 to ≤5% showed the lowest risk of each cardiovascular event. Both directions of weight change were associated with an increased cardiovascular risk. Stepwise increases in the risks of MI, IS, AF, HF, and all-cause death were noted with progressive weight gain (all P &amp;lt; 0.0001). Similarly, the more weight loss occurred, the higher the cardiovascular risks observed (all P &amp;lt; 0.0001). The U-shaped associations were consistently observed in both univariate and multivariate analyses. Explorative subgroup analyses also consistently showed a U-shaped association. CONCLUSIONS Both weight loss and gain &amp;gt;5% within a 2-year interval were associated with an increased risk of major cardiovascular events in patients with T2DM.
Risk of variceal hemorrhage and pretransplant mortality in children with biliary atresia
Authors: Lee M. Bass, Wen Ye, Kieran Hawthorne, Daniel H. Leung, Karen F. Murray, Jean P. Molleston, Rene Romero, Saul Karpen, Philip Rosenthal, Kathleen M. Loomes, Kasper S. Wang, Robert H. Squires, Alexander Miethke, Vicky L. Ng, Simon Horslen, M. Kyle Jensen, Ronald J. Sokol, John C. Magee, Benjamin L. Shneider
Journal: Hepatology (2022)

Abstract Background and Aims The natural history of gastroesophageal variceal hemorrhage (VH) in biliary atresia (BA) is not well characterized. We analyzed risk factors, incidence, and outcomes of VH in a longitudinal multicenter study. Approach and Results Participants enrolled in either an incident (Prospective Database of Infants with Cholestasis [PROBE]) or prevalent (Biliary Atresia Study of Infants and Children [BASIC]) cohort of BA were included. Variceal hemorrhage (VH) was defined based on gastrointestinal bleeding in the presence of varices accompanied by endoscopic or nontransplant surgical intervention. Cumulative incidence of VH and transplant‐free survival was compared based on features of portal hypertension (e.g., splenomegaly, thrombocytopenia) and clinical parameters at baseline in each cohort (PROBE: 1.5 to 4.5 months after hepatoportoenterostomy [HPE]; BASIC: at enrollment &gt; 3 years of age). Analyses were conducted on 869 children with BA enrolled between June 2004 and December 2020 (521 in PROBE [262 (51%) with a functioning HPE] and 348 in BASIC). The overall incidence of first observed VH at 5 years was 9.4% (95% CI: 7.0–12.4) in PROBE and 8.0% (5.2–11.5) in BASIC. Features of portal hypertension, platelet count, total bilirubin, aspartate aminotransferase (AST), albumin, and AST‐to‐platelet ratio index at baseline were associated with an increased risk of subsequent VH in both cohorts. Transplant‐free survival at 5 years was 45.1% (40.5–49.6) in PROBE and 79.2% (74.1–83.4) in BASIC. Two (2.5%) of 80 participants who had VH died, whereas 10 (12.5%) underwent transplant within 6 weeks of VH. Conclusions The low risk of VH and associated mortality in children with BA needs to be considered in decisions related to screening for varices and primary prophylaxis of VH.
IN-HOSPITAL AND POST-DISCHARGE SAFETY OF ATHERECTOMY IN PATIENTS UNDERGOING LOWER EXTREMITY REVASCULARIZATION: INSIGHTS FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY PERIPHERAL VASCULAR INTERVENTION (NCDR PVI) REGISTRY
Authors: Mazen Saadi Albaghdadi, Michael N. Young, Ehrin Armstrong, Peter Philip Monteleone, Rasha Al-Bawardy, Beau Michael Hawkins, Kevin Kennedy, Eric Alexander Secemsky
Journal: Journal of the American College of Cardiology (2022)
Body Mass Index and Clinical Outcomes in Persons Living With Cystic Fibrosis—Is Bigger Always Better?
Authors: Christina S. Thornton
Journal: JAMA Network Open (2022)

Rita Nagy, MD; Noémi Gede, PhD; Klementina Ocskay, MD; Bernadett-Miriam Dobai, MD; Alan Abada, MD; Zsófia Vereczkei; Piroska Pázmány, MD; Dorottya Kató; Péter Hegyi, MD, PhD, DSc; Andrea Párniczky, MD, PhD
Left Ventricular Thrombus Following Acute Myocardial Infarction
Authors: Anton Camaj, Valentin Fuster, Gennaro Giustino, Solomon W. Bienstock, David Sternheim, Roxana Mehran, George D. Dangas, Annapoorna Kini, Samin K. Sharma, Jonathan Halperin, Marc R. Dweck, Martin E. Goldman
Journal: Journal of the American College of Cardiology (2022)
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Alberto A. Chiappori, Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa, Margaret L. Barlow, Zhihua Chen, Dung Tsa Chen, Amer A. Beg, Theresa A. Boyle, Julio Castro, Liza Morgan, Erick Morris, Mehreteab Aregay, Felipe K. Hurtado, Luigi Manenti, Scott Antonia
Journal: Clinical Cancer Research (2022)

Abstract Purpose: The adenosine 2A receptor (A2AR) mediates the immunosuppressive effects of adenosine in the tumor microenvironment and is highly expressed in non–small cell lung cancer (NSCLC). Taminadenant (PBF509/NIR178) is an A2AR antagonist able to reactivate the antitumor immune response. Patients and Methods: In this phase I/Ib, dose-escalation/expansion study, patients with advanced/metastatic NSCLC and ≥1 prior therapy received taminadenant (80–640 mg, orally, twice a day) with or without spartalizumab (anti–programmed cell death-1, 400 mg, i.v., every 4 weeks). Primary endpoints were safety, tolerability, and feasibility of the combination. Results: During dose escalation, 25 patients each received taminadenant alone or with spartalizumab; 19 (76.0%) and 9 (36.0%) had received prior immunotherapy, respectively. Dose-limiting toxicities (all Grade 3) with taminadenant alone were alanine/aspartate aminotransferase increase and nausea [n = 1 (4.0%) each; 640 mg], and in the combination group were pneumonitis [n = 2 (8.0%); 160 and 240 mg] and fatigue and alanine/aspartate aminotransferase increase [n = 1 (4.0%) each; 320 mg]; pneumonitis cases responded to steroids rapidly and successfully. Complete and partial responses were observed in one patient each in the single-agent and combination groups; both were immunotherapy naïve. In the single-agent and combination groups, 7 and 14 patients experienced stable disease; 7 and 6 patients were immunotherapy pretreated, respectively. Conclusions: Taminadenant, with and without spartalizumab, was well tolerated in patients with advanced NSCLC. The maximum tolerated dose of taminadenant alone was 480 mg twice a day, and 240 mg twice a day plus spartalizumab. Efficacy was neither a primary or secondary endpoint; however, some clinical benefit was noted regardless of prior immunotherapy or programmed cell death ligand-1 status.
HSR22-132: Evolution of an Advanced Practice Provider (APP) Clinical Advancement Program (CAP): From Development and Implementation to Present
Authors: Jennifer Browning, Lisa Parks
Journal: Journal of the National Comprehensive Cancer Network (2022)

"HSR22-132: Evolution of an Advanced Practice Provider (APP) Clinical Advancement Program (CAP): From Development and Implementation to Present" published on 31 Mar 2022 by National Comprehensive Cancer Network.
Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations
Authors: Qiong Shi, Lin Liu, Jianru Chen, Weigang Zhang, Weinan Guo, Xiao Wang, Huina Wang, Sen Guo, Qiao Yue, Jingjing Ma, Yu Liu, Guannan Zhu, Tao Zhao, Jianhong Zhao, Ying Liu, Tianwen Gao, Chunying Li
Journal: Clinical Cancer Research (2022)

Acral melanoma is the major subtype of melanoma seen in Asian patients with melanoma and is featured by its insidious onset and poor prognosis. The genomic study that elucidates driving mutational events is fundamental to the development of gene-targeted therapy. However, research on genomic profiles of acral melanoma in Asian patients is still sparse.We carried out whole-exome sequencing (WES) on 60 acral melanoma lesions (with 55 primary samples involved), targeted deep sequencing in a validation cohort of 48 cases, RNA sequencing in 37 acral melanoma samples (all from the 60 undergoing WES), and FISH in 233 acral melanoma specimens (54 of the 60 undergoing WES included). All the specimens were derived from Asian populations.BRAF, NRAS, and KIT were discerned as significantly mutated genes (SMG) in acral melanoma. The detected COSMIC signature 3 related to DNA damage repair, along with the high genomic instability score, implied corresponding pathogenesis of acral melanoma. Moreover, the copy number gains of EP300 were associated with the response of acral melanoma to targeted therapy of A485 (a p300 inhibitor) and immune checkpoint blockade treatment. In addition, the temporal order in mutational processes of the samples was reconstructed, and copy-number alterations were identified as early mutational events.Our study provided a detailed view of genomic instability, potential therapeutic targets, and intratumoral heterogeneity of acral melanoma, which might fuel the development of personalized strategies for treating acral melanoma in Asian populations.
Forecasted and Observed Drug Overdose Deaths in the US During the COVID-19 Pandemic in 2020
Authors: Abigail R. Cartus, Yu Li, Alexandria Macmadu, William C. Goedel, Bennett Allen, Magdalena Cerdá, Brandon D. L. Marshall
Journal: JAMA Network Open (2022)

This cross-sectional study uses data from the National Vital Statistics System to compare forecasted numbers of drug overdose deaths in the US in the latter 43 weeks of 2020 with the observed number of overdose deaths in that period.
Translational approaches to understanding resilience to Alzheimer’s disease
Authors: Sarah M. Neuner, Maria Telpoukhovskaia, Vilas Menon, Kristen M.S. O’Connell, Timothy J. Hohman, Catherine C. Kaczorowski
Journal: Trends in Neurosciences (2022)

Individuals who maintain cognitive function despite high levels of Alzheimer's disease (AD)-associated pathology are said to be 'resilient' to AD. Identifying mechanisms underlying resilience represents an exciting therapeutic opportunity. Human studies have identified a number of molecular and genetic factors associated with resilience, but the complexity of these cohorts prohibits a complete understanding of which factors are causal or simply correlated with resilience. Genetically and phenotypically diverse mouse models of AD provide new and translationally relevant opportunities to identify and prioritize new resilience mechanisms for further cross-species investigation. This review will discuss insights into resilience gained from both human and animal studies and highlight future approaches that may help translate these insights into therapeutics designed to prevent or delay AD-related dementia.
Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant
Authors: Ai-ris Y. Collier, Catherine M. Brown, Katherine A. McMahan, Jingyou Yu, Jinyan Liu, Catherine Jacob-Dolan, Abishek Chandrashekar, Dylan Tierney, Jessica L. Ansel, Marjorie Rowe, Daniel Sellers, Kunza Ahmad, Ricardo Aguayo, Tochi Anioke, Sarah Gardner, Mazuba Siamatu, Lorraine Bermudez-Rivera, Michele R. Hacker, Lawrence C. Madoff, Dan H. Barouch
Journal: Science Translational Medicine (2022)

Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have been reported frequently in vaccinated individuals with waning immunity. In particular, a cluster of over 1000 infections with the SARS-CoV-2 delta variant was identified in a predominantly fully vaccinated population in Provincetown, Massachusetts in July 2021. In this study, vaccinated individuals who tested positive for SARS-CoV-2 ( n = 16) demonstrated substantially higher serum antibody responses than vaccinated individuals who tested negative for SARS-CoV-2 ( n = 23), including 32-fold higher binding antibody titers and 31-fold higher neutralizing antibody titers against the SARS-CoV-2 delta variant. Vaccinated individuals who tested positive also showed higher mucosal antibody responses in nasal secretions and higher spike protein–specific CD8 + T cell responses in peripheral blood than did vaccinated individuals who tested negative. These data demonstrate that fully vaccinated individuals developed robust anamnestic antibody and T cell responses after infection with the SARS-CoV-2 delta variant. Moreover, these findings suggest that population immunity will likely increase over time by a combination of widespread vaccination and breakthrough infections.
Inequitable Resource Allocation Amidst a Pandemic—A Crisis Within a Crisis
Authors: Hayley B. Gershengorn
Journal: JAMA Network Open (2022)

Elisabeth D. Riviello, MD, MPH; Tenzin Dechen, MPH; Ashley L. O'Donoghue, PhD; Michael N. Cocchi, MD; Margaret M. Hayes, MD; Rose L. Molina, MD, MPH; Nicole H. Moraco, MD, MA; Anne Mosenthal, MD; Michael Rosenblatt, MD, MPH, MBA; Noa Talmor, BS; Daniel P. Walsh, MD; David N. Sontag, JD, MBE; Jennifer P. Stevens, MD, MS